Balchem (BCPC) Expected to Announce Earnings on Thursday

Balchem (NASDAQ:BCPC - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, July 31st. Analysts expect Balchem to post earnings of $1.25 per share and revenue of $250.31 million for the quarter.

Balchem (NASDAQ:BCPC - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The basic materials company reported $1.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.25 by ($0.03). Balchem had a net margin of 14.16% and a return on equity of 12.01%. The business had revenue of $250.52 million during the quarter, compared to the consensus estimate of $245.70 million. During the same quarter in the previous year, the firm posted $1.03 EPS. The company's revenue for the quarter was up 4.5% compared to the same quarter last year. On average, analysts expect Balchem to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Balchem Trading Up 0.1%

NASDAQ:BCPC traded up $0.18 during trading hours on Monday, hitting $153.02. 125,681 shares of the stock were exchanged, compared to its average volume of 143,675. The company's 50 day moving average is $163.15 and its two-hundred day moving average is $162.67. Balchem has a twelve month low of $145.70 and a twelve month high of $186.03. The company has a quick ratio of 1.40, a current ratio of 2.44 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $4.99 billion, a P/E ratio of 36.70, a price-to-earnings-growth ratio of 3.30 and a beta of 0.89.

Institutional Trading of Balchem

Institutional investors and hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. grew its position in Balchem by 53.6% during the first quarter. Goldman Sachs Group Inc. now owns 246,883 shares of the basic materials company's stock worth $40,983,000 after buying an additional 86,132 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Balchem by 9.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 100,860 shares of the basic materials company's stock worth $16,743,000 after acquiring an additional 9,118 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Balchem by 124.4% during the 1st quarter. AQR Capital Management LLC now owns 5,074 shares of the basic materials company's stock worth $842,000 after acquiring an additional 2,813 shares in the last quarter. Jones Financial Companies Lllp boosted its position in shares of Balchem by 1,768.2% during the 1st quarter. Jones Financial Companies Lllp now owns 822 shares of the basic materials company's stock worth $136,000 after acquiring an additional 778 shares in the last quarter. Finally, Advisors Asset Management Inc. acquired a new stake in shares of Balchem during the 1st quarter worth approximately $27,000. Institutional investors own 87.91% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on BCPC. HC Wainwright set a $180.00 price target on shares of Balchem and gave the stock a "buy" rating in a research report on Monday, April 28th. Wall Street Zen lowered shares of Balchem from a "buy" rating to a "hold" rating in a research note on Wednesday, May 21st.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.